Thursday, August 28, 2014 12:53:11 PM
Date : 08/28/2014 @ 12:25PM
Source : Business Wire
Stock : Acusphere, Inc. (PN) (ACUS)
Quote : 0.6 -0.065 (-9.77%) @ 12:25PM
Acusphere Withdraws its European Marketing Authorization Application for Imagify
http://ih.advfn.com/p.php?pid=nmona&article=63404450&symbol=ACUS
Acusphere, Inc. (USOTC:ACUS)
Intraday Stock Chart
Today : Thursday 28 August 2014
Click Here for more Acusphere, Inc. Charts.
Acusphere, Inc. (ACUSD.PK) announced today the strategic decision to voluntarily withdraw its Marketing Authorization Application (MAA) submitted to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Imagify™ (Perflubutane Polymer Microspheres for Injectable Suspension). The Company intends to continue working with the U.S. Food and Drug Administration (FDA) on the development of Imagify.
“The withdrawal of the MAA is a difficult but necessary decision at this time. We are choosing to focus our resources on a pivotal trial in the U.S. to strengthen Imagify’s total data package for future partnering discussions and global regulatory submissions,” said Mark Leuchtenberger, President and Chief Executive Officer of Acusphere. “The withdrawal of the MAA in Europe does not affect the status of Imagify’s Special Protocol Assessment with the FDA and we remain committed to completing its clinical development.”
In May 2011, Acusphere reached an agreement with the FDA, under a Special Protocol Assessment (SPA), on the design of a placebo controlled trial to demonstrate that stress ultrasound with Imagify has superior efficacy to stress ultrasound without Imagify.
About Acusphere, Inc.
Acusphere, Inc. (ACUSD.PK) is a specialty pharmaceutical company focused on the development and regulatory approval of our lead product candidate, Imagify™ (Perflubutane Polymer Microspheres for Injectable Suspension). Imagify is a cardiovascular drug for the detection of coronary artery disease, the leading cause of death in the United States and Europe. Imagify was created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles, which were customized to control the delivery of gas needed for ultrasound myocardial perfusion assessment. For more information about Acusphere visit the Company’s website (www.acusphere.com).
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM